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A B S T R A C T  
 
COVID-19 has been declared by WHO as a pandemic since March 2020. The pandemic has caused 
major deaths in the world and has become the candidate for the third largest pandemic in history 
after the Black Death pandemic and the Spanish Flu pandemic. Many conditions have made the 
deaths in the COVID-19 pandemic become large, including collision with the obesity epidemic. The 
aim of this literature review is to discuss the relationship between obesity as a risk factor for high 
mortality COVID-19 and its management. 
 









Obesity is Epidemic and COVID-19 is 
Pandemic  
Endemic disease is a disease that 
appears and becomes characteristic in certain 
areas. This disease will always exist in the area, 
but with a low frequency or number of cases. 
An epidemic occurs when a disease has spread 
rapidly to a certain region or country and 
begins to affect the population of that region 
or country. A pandemic is a disease outbreak 
that occurs widely throughout the world. In 
other words, this disease has become a 
common problem for all citizens of the world. 
Coronavirus disease 2019 (COVID-19) 
has been declared by WHO as a pandemic on 
March 9, 2020.(1) At the time of writing this 
article, the number of world population 
infected with the SARS-CoV-2 has reach 
208,019,700 and in Indonesia it has reached 
3,854,354. Deaths caused by COVID-19 have 
reached 4,375,028 worldwide, and 117,588 in 
Indonesia.(2) One of the risk factors related to 
mortality in COVID-19 is obesity.(3) 
In 2016, the World Health Organization 
(WHO) revealed that 39% (1.9 billion people) of 
the world's population were overweight, of 
which more than 650 million were obese. 
There were 340 million adolescents (5-19 years 
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old) who were overweight and obese in the 
same year.(4) There were 38 million children 
under 5 years old who were overweight and 
obese in 2019. The global incidence of obesity 
has nearly tripled since 1975, according to the 
WHO. Much of the world's population resides 
in countries where more people are killed by 
obesity and overweight than underweight.(5) 
In Indonesia, basic public health survey 
or known as Riset Kesehatan Dasar (Riskesdas) 
2007 showed that 10.5% of the population 
were obese, Riskesdas 2013 showed 14.8% of 
the population were obese and Riskesdas 2018 
showed 21.8% of the population were obese 
and 20% of elementary school children were 
overweight and obese.(6-8) Obesity is a form of 
malnutrition besides stunting and wasting.(9) 
Obesity has become rapidly increased in 
the United States since 1990s with worsen 
lifestyle.(10) The American Centre for Disease 
Control and Prevention (CDC), in a report 
dated February 3, 2021, mentioned about 
confirmed medical conditions related to the 
severity of COVID-19 (Table 1). They divided 
these medical conditions into: (1) might be at 
an increased risk and (2) at increased risk for 
severe illness from the virus that causes 
COVID-19. Overweight was included in “might 
be at an increased risk”, while obesity was 
included in “increased risk”.(11) 
The aim of this article is to review all 
aspects of obesity, including its definition, 
diagnosis, epidemic status and its relationship 
to the COVID-19 pandemic. Concerning the 
COVID-19 pandemic, we discuss how the 
pathophysiology of obesity can aggravate 
COVID-19 and how to manage it. Controlling 
obesity is expected to reduce COVID-19 
morbidity and mortality.
Table 1. Medical Conditions as Risk of Severe COVID-19.(11) 
Might be at an increased risk  At increased risk  
− Asthma (moderate-to-severe) 
− Cerebrovascular disease  
− Cystic fibrosis 
− Hypertension or high blood pressure 
− Immunocompromised state from blood or bone 
marrow transplant, immune deficiencies, HIV, 
use of corticosteroids, or use of other 
immunosuppression medicines 
− Neurologic conditions, such as dementia 
− Liver disease 
− Overweight (BMI > 25 kg/m2, but < 30 kg/m2) 
− Pulmonary fibrosis  
− Thalassemia  
− Type 1 diabetes mellitus 
− Cancer 
− Chronic kidney disease 
− Chronic obstructive pulmonary disease 
− Down syndrome 
− Heart conditions, such as heart failure, coronary 
artery disease, or cardiomyopathies 
− Immunocompromised state from solid organ 
transplant 
− Obesity (body mass index [BMI] of 30 kg/m2 or 
higher but < 40 kg/m2) 
− Severe obesity (BMI ≥ 40 kg/m2) 
− Pregnancy 
− Sickle cell disease 
− Smoking 
− Type 2 diabetes mellitus 
  
Definition and Pathophysiology of Obesity  
Obesity is the accumulation of excessive 
fat due to an imbalance between energy intake 
and energy expenditure for a long period of 
time. Energy intake that exceeds energy 
expenditure, will cause obesity. Energy intake 
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comes from foods and drinks calorie. Energy 
expenditure includes: (1) energy used for 
organs works such as digesting, absorbing 
food and food metabolism, named as the 
thermic effect of food (TEF), (2) energy used at 
rest, or resting metabolic rate (RMR) and (3) 
energy used for physical activity.(12) 
Criteria of Obesity  
Obesity can be determined based on the 
following examinations. First, measuring body 
mass index, which is obtained from body 
weight (kg) divided by the square of height 
(m2). Second, measuring waist circumference 
in standing position. The tape circles the 
abdomen in the middle between the arch of 
the lower ribs and the iliac crests. A body mass 
index of more than 27 kg/m2 and/or a waist 
circumference of more than 80 cm for women 
and more than 90 cm for men meet the criteria 
of obesity.(13,14) 
Aetiology of Obesity  
The causes of obesity include: sedentary 
lifestyle, overeating, genetic factors, hormonal 
imbalances, use of illegal drugs or potions, 
psychological factors and environmental 
factors. Diets related to obesity are: eating 
large amount of sugar and salt, eating less 
vegetables and fruit, irregular eating 
schedules, skipping breakfast and increasing 
lunch or dinner portion, snacking frequently, 
and processing food using a lot of oil, thick 
coconut milk and lots of sugar.(14) 
Sedentary activities are activities that 
are performed outside of bedtime, with a 
characteristic of very little calorie output, less 
than 1.5 metabolic equivalent (MET). Examples 
of sedentary activities are: lying down or 
sitting for long time, such as watching 
television, playing video games, sitting for a 
long time in front of the computer, and lack of 
exercise.(15) 
Genetic factor and hormonal 
imbalances also contribute to obesity. Many 
genes involved in obesity are shown in Table 2 
and hormones involved in obesity are shown in 
Table 3.
Table 2. Genes Involved in Obesity.(16,17) 
Gene Symbol Gene Name Gene Product and Role in Metabolism 
ADIPOQ Adipocyte-, C1q-, and collagen domain-
containing 
Produced by adipocytes, adiponectin increases 
energy expenditure 
FTO Fat mass- and obesity-associated gene Increase food intake 
LEP Leptin Produced by adipocyte 
LEPR Leptin receptor When it binds to leptin, it inhibits appetite 
INSIG2 Insulin-induced gene 2 Regulation of cholesterol and fatty acid synthesis 
MC4R Melanocortin 4 receptor When it binds to alpha-melanocyte stimulating 
hormone, it stimulates appetite 
PCSK1 Proprotein convertase subtilisin/kexin type 1 Regulates insulin biosynthesis 
PPARG Peroxisome proliferator-activated receptor 
gamma 
Stimulates fatty acid uptake and adipose tissue 
formation 
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Many other factors contribute to 
obesity. It is more likely that pregnant women 
who smoke or who are overweight or obese 
will have children who are overweight or 
obese.(19) The health choices of people can be 
affected by environmental systems, schools, 
workplaces, income, media, and access to 
health care, and the availability of healthy 
food. In order to be more easily active in 
physical activity and healthy eating, it is 
necessary to build a healthy atmosphere.(20) 
Study suggests that when affected by mental 
health issues such as depression, anxiety, or 
other feelings, certain individuals appear to 
over-eat.(21) Ghrelin and leptin, which 
contribute to obesity, can interfere with lack of 
sleep.(22) Sleep-deprived individuals may be 
less driven to exercise, resulting in less burned 
calories. Obesity-associated medicines are: 
some antidiabetics, antipsychotics, 
antidepressants, anticonvulsants, hormonal 
agents, anti-inflammatory agents, 
corticosteroids, and antihistamines.(23)
Table 3. Hormones Involved in Metabolism.(15) 
Hormone name  Role in Metabolism 
Thyroid hormones Hypothyroidism causes decrease metabolism and weight gain 
Leptin Excess leptin, which is produced by excess adipose tissue, makes the brain 
insensitive to signals of satiety 
Insulin Insulin helps store energy reserves from glucose in the form of fat storage 
Estrogen Estrogen that is too low or too high can cause weight gain 
Cortisol High levels can cause hyperinsulinemia and visceral fat accumulation 
Progesterone Decreased levels cause weight gain 
Ghrelin Increased levels increase appetite 
Testosterone  Decreased levels cause weight gain 
Melatonin Decreased levels cause weight gain 
Glucocorticoid Increased levels cause weight gain 
Glucagon like peptide 1 (GLP1) and 
dipeptidyl peptidase-4 (DPP4) 
Increased DPP4 and decreased GLP-1 levels are associated with obesity 
 
Body Image Versus Body Mass Index 
Many obese people believe they have 
healthy weight. Researchers asked volunteers 
in a survey of 2,056 obese individuals in Dallas 
to select figures of ideal body shape along with 
one that most closely resembles their body 
shape. There were 8% of respondents 
preferring the same or bigger body shape than 
them, reflecting a misunderstanding regarding 
a healthy weight. People who misrepresent the 
size of their body feel healthier than people 
who are conscious of their obesity.(24) 
Health Consequences of Obesity 
The physical effects of obesity include: 
sleep apnea, asthma, breast cancer, intestinal 
disease, fatty liver, gallbladder disease, kidney 
disease, prostate disease, varicose veins, 
stroke, diabetes mellitus, hypertension and 
coronary heart disease, abnormal reproductive 
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hormones, polycystic ovary syndrome, 
osteoarthritis of the knee and pelvis.(14) The 
psychological effects of obesity include: 
movement becomes slower resulted in 
decreased work productivity, reduced self-
confidence, less attractive appearance and 
withdrawing from social interactions.(25) 
The Difference between Non-Obese and 
Obese Adipose Tissue  
In non-obese adipose tissue, the profiles 
shown are anti-inflammatory, antioxidant, 
optimal insulin sensitivity, and normal 
angiogenesis. A healthy immune system 
supported by normal adipose tissue protect us 
from disease. In contrast, in obese people, what 
occurs is predominantly pro-inflammatory 
profile, high oxidative stress, insulin resistance, 
and poor angiogenesis. The effects on the 
immune system are: decreased function of T 
cells and macrophages, decreased response to 
vaccination, and decreased response to 
antivirals.(26) 
Molecular Mechanism of Severity in Obese 
COVID-19 Patients  
Adipose Tissue as Reservoir of SARS-CoV-2 
Obese adipose tissue is also thought to 
be a reservoir for SARS-CoV-2. Adipose tissue in 
non-obese people shows moderate expression 
of molecules known to act as SARS-CoV-2 
receptors, such as angiotensin converting 
enzyme 2 (ACE2), Dipeptidyl peptidase-4 
(DPP4), CD147, and furin. These molecules are 
highly expressed in obese adipose tissue. It is 
also suspected that SARS-CoV-2 circulates by 
attaching to circulating ACE2 and DPP4, making 
it easy to spread throughout the body. In 
addition, the DPP4 circulating in large amounts 
in obese can increase inflammation, fibrosis, 
and excessive immune response.(27) In obese 
adipose tissue itself, the viruses replicate, 
making body difficult to clear them.(28) 
 
Increased Ratio of Angiotensin II to 
Angiotensin (1-7) 
Obese adipose tissue produces 
angiotensinogen, which is subsequently 
converted with the help of renin to angiotensin 
I and then angiotensin I with the help of ACE is 
converted to angiotensin II. Angiotensin II is a 
potent vasoconstrictor. Angiotensin I is 
converted to angiotensin II, and with the help of 
ACE2 it is converted to angiotensin (1-9) and 
angiotensin II is converted with the help of 
ACE2 to angiotensin (1-7). SARS-CoV-2 binding 
to ACE2 inhibits conversion to angiotensin (1-
7), and increases the ratio of angiotensin II to 
angiotensin (1-7). This will trigger 
vasoconstriction, inflammation, fibrosis, and 
oxidation. Consequently, lung injury occurs, 
pulmonary vascular permeability increases and 
induces pulmonary oedema and acute 
respiratory distress syndrome.(29) In addition, 
there are many comorbidities associated with 
obesity, including: hypertension, type 2 
diabetes mellitus, cardiovascular disease, 
inflammation of epicardial adipose tissue, 
atherosclerosis, renal disorders, cancer, and 
psychological/psychiatric disorders. All can 
aggravate COVID-19.(30) 
Immunosuppression State and Excess 
Proinflammatory Cytokines  
Adipose tissue produces excess leptin, 
actually in an attempt to suppress appetite, but 
this excessive leptin will increase the 
production of interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-α) which are 
proinflammatory.(31) In individuals with obesity, 
the intestinal lipopolysaccharide (LPS) 
composition may be changed from 
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immunosilent/immunoinhibitory subtypes of 
Bacteroidetes LPS, to subtypes of 
proinflammatory LPS due to gut microbiome 
dysbiosis. In addition, presence of mixed 
infection with bacteria that is very easy to occur 
in obese patients, especially with comorbid 
type 2 diabetes mellitus, also increases the 
production of lipopolysaccharide and 
endotoxemia which then activates 
macrophages to produce IL-6 and TNF-α, thus 
increasing inflammation.(32) Endotoxemia also 
increases IL-10 which in turn activates dendritic 
cells to induce an immunosuppressive state, 
increases susceptibility to viral infections.(33) 
Viral infection itself also induces 
immunosuppression.(34) These conditions will 
form a vicious cycle of worsening COVID-19. 
Impaired Tissue Remodeling  
In non-obese COVID-19 patients, 
pulmonary vasoconstriction and remodeling 
also occur, but injury is prevented, and due to 
angiogenesis is working well, a vascular shunt 
may occur to compensate and improve the 
ventilation perfusion ratio that is impaired due 
to lung parenchymal damage.(30) And in non-
obese, there are no other comorbid conditions 
that aggravate the condition. 
Poor Pulmonary Conditions 
The pulmonary condition of obese 
COVID-19 patients can become very severe as a 
result of: dysfunction of the resident 
mesenchymal stem cell, defects in the 
respiratory tract (decreased mucociliary 
escalator), chronic inflammation, immune 
system deregulation, mechanical defects due 
to diaphragmatic movement disorders due to 
oppression by massive abdominal adipose 
tissue, and pulmonary artery hypertension. 
These conditions will aggravate the infection, 
inflammation persistence, increase fibrosis, 
functional failure, and increase the need for 
intubation and artificial ventilation.(27) Related 
to the physiological function of the lungs, in 
obese COVID-19 patients, there are a reduction 
in force expiratory volume, a reduction in force 
vital capacity, and an increase in thoracic 
oppression.(27,35) 
Poor Extrapulmonary Conditions 
The extrapulmonary conditions that are 
affected by obesity, which further increase the 
worsening of COVID-19 in obesity are as follows. 
In the heart: heart failure preserved ejection 
function, cardiomyopathy and increased risk of 
atrial fibrillation. In the kidneys: podocyte 
dysfunction and hypertrophy, hypertrophy and 
glomerular capillary hypertension, 
glomerulomegaly, glomerulosclerosis, 
proteinuria and end state renal disease. In 
vascular: endothelitis, endothelial dysfunction 
associated with apoptosis, vasoconstriction 
and vasodilation imbalances, prothrombotic 
and proatherogenic conditions, platelet 
hyperactivity, increased leukocyte adhesion 
and oxidation. In coagulation: adipocytokine 
hyperactivity, hypercoagulation and low 
fibrinolysis.(35) 
Obesity itself increases inflammation in 
sustentacular cells of olfactory mucosa and 
tongue taste buds. This condition reduces the 
smell and taste perception of obese patients. 
ACE2, which is the SARS-CoV-2 receptor, is 
found on sustentacular cells and also on the 
tongue. In COVID-19 patients, inflammation 
occurs in these cells as well. In obese patients, 
of course, it becomes even more severe due to 
even before contracting COVID-19, they already 
experience inflammation. In fact, pre-existing 
inflammation, which reduces smell and taste, 
will mask the anosmia and/or ageusia from 
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COVID-19 and thus delay diagnosis. Whereas in 
non-obese people, the presence of anosmia 
and/or ageusia can be an early indication of 
COVID-19 infection.(36) In obese persons, the gut 
microbiota changes, make it susceptible to 
microbes’ entry and replication, including 
SARS-CoV-2 in the intestines.(32) The 
gastrointestinal tract itself is very abundant in 
ACE2 receptors which is well known as the entry 
route for SARS-CoV-2 in the body.(37) 
Micronutrients Deficiency in Obese Patients 
Obese patients despite appearing to be 
over nourished, in fact, many of them have 
nutritional deficiencies, especially 
micronutrients. Many of them are deficient in 
vitamin D, ascorbic acid, zinc and selenium.(38) 
As is well known, these micronutrients are 
related to the function of the immune system. 
Many studies have shown that the severity of 
COVID-19 is also related to deficiency of these 
substances.(39) 
Table 4. Micronutrients deficiency in Obesity.(38) 
Micronutrient 
Prevalence of Deficiency in 
Obesity 
Thiamine B1 15–29% 
Pyridoxine B6 0–11% 
Cobalamin B12 3–8% 
Folic acid 3-4% 
Ascorbic acid  35–45% 
Vitamin A 17% 
Vitamin D 80–90%c 




Increased Morbidity and Mortality 
COVID-19 with obesity increases 
hospitalization, intensive care, invasive 
mandatory ventilation requirements, and 
mortality for patients. Excess visceral fat tissue 
is associated with the severity of COVID-19.((40),41) 
Poor Response to Vaccination 
The influenza vaccine response is 
reduced in obesity. Hemagglutination inhibitor 
titers were similar in obese and normal weight 
hosts measured immediately after vaccination, 
but decreased more rapidly in the obese 
population. The switching of IgM to IgG classes 
is also impaired. The cellular immune response 
to vaccination in obesity has been shown to 
decrease activation and decreased 
maintenance of memory T cells. COVID-19 
vaccine response in obese has not been known 
yet, but might be the same.(42) 
General Management of Obesity 
The management of obesity includes: 
limiting intake of sugar, salt and fat, consuming 
more fruits and vegetables and doing physical 
activity to lose weight to normal. A balanced 
low-energy diet is a reduction of 500-1,000 kcal 
of energy from daily needs, by: reducing the 
consumption of complex and simple 
carbohydrates, reducing fat consumption, such 
as processing fried foods, using thick coconut 
milk, butter, and margarine, and eating a T 
pattern plate.(14) Recognize the emotions of 
eating, avoid distracting emotions by eating 
lots of food when angry, stressed, bored and 
others are very important.(43) 
Obesity can occur at any age, even in 
young children. But with age, hormonal 
changes and a sedentary lifestyle increase the 
risk of obesity. In addition, the amount of 
muscle in the body tends to decrease with age. 
Generally, lower muscle mass leads to 
decreased metabolism. These changes also 
reduce calorie requirements and can make 
weight loss more difficult.(44) 
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The Endocrine Society suggests that 
alteration of diet, exercise and behavior be part 
of every solution to obesity management. Since 
certain antidiabetic are associated with weight 
gain, medications that promotes weight loss or 
have no impact on body weight should be 
offered to diabetics who are obese or 
overweight as first and second-line treatments. 
For type 2 diabetes mellitus and obesity, 
metformin is the first-line agent. Glucagon-like 
peptide-1 analogues (GLP-1) or sodium-
glucose-linked transporter-2 (SGLT-2) 
inhibitors are second-line drugs. Angiotensin-
converting enzyme inhibitors, angiotensin 
receptor blockers and calcium channel 
blockers can be used as first-line treatment for 
high blood pressure. They are effective 
medication for blood pressure that are less 
than beta-adrenergic antagonists to lead to 
weight gain.(45) 
When patients require weight gain-
related medicines, such as antidepressants, 
antipsychotic and antiepileptic medicines, they 
should be fully advised and given an estimation 
of body weight impact of each choice. The 
weight and waist circumference of patients 
who are taking antiretroviral therapy should be 
tracked. Non-hormonal contraception is 
recommended for women with a BMI > 27 kg/m2 
with comorbidities or BMI > 30 kg/m2 pursuing 
contraception; if they cannot avoid it, choose 
oral rather than injection due to injection 
contraception can increase weight. In patients 
with chronic inflammatory disease, it is best to 
use non-steroidal anti-inflammatory drugs and 
other anti-rheumatic drugs whenever possible, 
as corticosteroids typically result in weight 
gain. Weight gain is limited in antihistamines 
with less central nervous system activity (less 
sedation) compared to those with more 
sedation. Weight loss pharmacological therapy 
is recommended using non-sympathomimetic 
medicines, such as lorcaserin and/or orlistat.(45) 
The other alternative in obesity 
management is bariatric surgery. The aim of 
bariatric surgery is to reduce the amount of 
food that stomach can accommodate or 
decrease the absorption of nutrients in the 
small intestine. Adults who have one of the 
following conditions will be considered for 
bariatric surgery: (1) extreme obesity, which is a 
body mass index greater than 40 and (2) obese 
with a body mass index ranging from 35 to 39.9, 
but with health issues, such as diabetes, heart 
disease, high blood pressure and sleep 
apnea.(46) 
Maintaining the weight, they have lost is 
often difficult for patients, particularly if they 
are surrounded by tasty, calorie-rich foods and 
depend on energy-saving devices every day. 
Cognitive and behavioral treatment may help 
preserve healthier habits for patients. 
Multidiscipline and support system are needed 
for successful management.(47) 
Management of Obesity with COVID-19  
Obesity impairs pulmonary ventilation 
related to diminished diaphragm movement 
caused by intra-abdominal fat tissue pressure. 
Obese patients, particularly men whom fat is 
distributed mainly in the visceral abdomen, will 
benefit from ventilation interventions. These 
include: high flow nasal cannula (HFNC), non-
invasive ventilation (NIV), high positive end-
expiratory pressure (PEEP) and they respond 
well to prone positioning and extracorporeal 
support.(48) When pronation is not possible due 
to patient discomfort or obesity, an extended 
semi-sitting or sitting position is preferable. 
Physiotherapists are highly recommended to 
be involved in patient management. 
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Adipose tissue is known to play role in the 
production of pro-inflammatory cytokines such 
as IL-6 and TNF-α.(31) Tocilizumab, a monoclonal 
antibody that competitively blocks IL-6 against 
its receptor (IL-6R), is proven to help with 
cytokine storms and has been recommended 
by professional organizations as part of COVID-
19 management.(49) COVID-19 may also benefit 
from drugs that inhibit TNF-α. Deficiencies of 
micronutrients related to the immune system, 
such as vitamin D, also must be corrected. 
Obesity in women is linked with higher 
androgen levels compared to non-obese.(50) 
High androgen levels, according to several 
observations, play role in the severity of COVID-
19 because androgen increases the expression 
of TMPRSS2. It is known that TMPRSS2 cleaves 
viral glycoprotein S, facilitating viral activation 
and representing one of the important host 
factors for SARS-CoV-2 pathogenicity.(51) Obese 
men have a greater COVID-19 burden than 
obese women.(52) It contradicts the theory that 
obese men have higher aromatase activity, 
which can convert testosterone to estradiol; 
and estrogens further suppress IL-6 
expression.(53,54) However, it can be explained by 
the fact that men have impaired estrogens 
receptor signaling, resulting in increased 
androgenic hormone and adipose tissue 
estrogens production.(55)Drugs that inhibit 
androgens action, such as spironolactone, may 
benefit for improvement. Androgen 
deprivation therapy has recently been shown 
to protect against COVID-19 in prostate cancer 
patients.(56) 
Camostat, a TMPRSS2 inhibitor, has been 
shown in to improve a variety of metabolic 
abnormalities in obese mice.(57) Studies of 
Camostat in COVID-19 patients also resulted in 
a faster recovery time and lower disease 
severity.(58,59) This medication may be beneficial 
to obese COVID-19 patients. 
Targeting the metabolism and 
distribution of cholesterol and lipids has been 
proposed as a novel strategy for treating viral 
infections. When cholesterol levels rise as a 
result of metabolic disorders, such as obesity, 
this may aggravate the severity of COVID-19. 
First, inflammatory cytokines promote the 
formation of 25-hydroxycholesterol, which in 
turn promotes adipose tissue inflammation.(60) 
Second, there is evidence that lipid rafts are 
required for viral entry by group ACE2 and 
TMPRSS2. Statins may disrupt this lipid raft 
composition. Statins also have anticoagulant 
and anti-inflammatory properties.(61) 
Mesenchymal stem cells are also 
considered to benefit obese COVID-19 patients 
via a variety of mechanisms. First, they provide 
an anti-inflammatory environment by reducing 
cytokine, chemokine and inflammatory cell 
infiltration. Second, they promote tissue 
remodeling and reduce fibrosis while 
improving pathological resolution. Third, they 
restore organ function and protein expression 
in cells of lungs, kidneys, cardiovascular system 
and nervous system.(62) 
C O N C L U S I O N  
 Obesity endemic aggravates COVID-19 
pandemic. Controlling obesity will reduce 
morbidity and mortality of COVID-19. 
R E F E R E N C E S 
1. WHO Director-General's opening remarks at the 
media briefing on COVID-19 - 11 March 2020 





Hasanah Dian  CRJIM2(2): November 2021 
 
 CRJIM • Vol 02• Number 2 • November 2021  Page | 213 
2. COVID-19 CORONAVIRUS PANDEMIC [Internet]. 
2021. viewed 16 August 2021. Available from: 
https://www.worldometers.info/coronavirus/  
3. Dietz W, Santos-Burgoa C. Obesity and its 
Implications for COVID-19 Mortality. Obesity 
(Silver Spring). 2020 Jun;28(6):1005.  
doi: 10.1002/oby.22818.  
4. Obesity [Internet]. Who.int. 2021 [cited 22 
February 2021]. Available from: 
https://www.who.int/health-topics/obesity 
5. Obesity and overweight [Internet]. Who.int. 2021 
[cited 22 February 2021]. Available from: 
https://www.who.int/news-room/fact-
sheets/detail/obesity-and-overweight 
6. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) 
2007 | Badan Penelitian dan Pengembangan 
Kesehatan [Internet]. Litbang.kemkes.go.id. 2021 
[cited 22 February 2021]. Available from: 
https://www.litbang.kemkes.go.id/laporan-riset-
kesehatan-dasar-riskesdas/ 
7. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) 
2013 | Badan Penelitian dan Pengembangan 
Kesehatan [Internet]. Litbang.kemkes.go.id. 2021 
[cited 22 February 2021]. Available from: 
https://www.litbang.kemkes.go.id/laporan-riset-
kesehatan-dasar-riskesdas/ 
8. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) 
2018 | Badan Penelitian dan Pengembangan 
Kesehatan [Internet]. Litbang.kemkes.go.id. 2021 
[cited 22 February 2021]. Available from: 
https://www.litbang.kemkes.go.id/laporan-riset-
kesehatan-dasar-riskesdas/ 
9. Fact sheets - Malnutrition [Internet]. Who.int. 
2021 [cited 22 February 2021]. Available from: 
https://www.who.int/news-room/fact-
sheets/detail/malnutrition 
10. Mitchell NS, Catenacci VA, Wyatt HR, et al. 
Obesity: overview of an epidemic. Psychiatr Clin 
North Am. 2011 Dec;34(4):717-32.  
doi: 10.1016/j.psc.2011.08.005.  
11. COVID-19 and Your Health [Internet]. Centers for 
Disease Control and Prevention. 2021 [cited 22 




12. Lam YY, Ravussin E. Analysis of energy 
metabolism in humans: A review of 
methodologies. Mol Metab. 2016 Sep 
20;5(11):1057-1071.  
doi: 10.1016/j.molmet.2016.09.005. 
13. WHO Expert Consultation. Appropriate body-
mass index for Asian populations and its 
implications for policy and intervention 
strategies. Lancet. 2004 Jan 10;363(9403):157-63.  
doi: 10.1016/S0140-6736(03)15268-3.  
14. FactsheetObesitasRe6 Epidemi Obesitas - 
kemkes.go.id [Internet]. [cited 2021Feb22]. 




15. Mansoubi M, Pearson N, Clemes SA, et al. Energy 
expenditure during common sitting and standing 
tasks: examining the 1.5 MET definition of 
sedentary behaviour. BMC Public Health. 2015 
May 29;15:516.  
doi: 10.1186/s12889-015-1851-x.  
16. Genes and obesity [Internet]. Centers for Disease 
Control and Prevention. Centers for Disease 




Ma X, Wang D, Zhao W, Xu L. Deciphering the Roles 
of PPARγ in Adipocytes via Dynamic Change of 
Transcription Complex. Front Endocrinol 
(Lausanne). 2018;9:473. Published 2018 Aug 21. 
doi:10.3389/fendo.2018.00473  
17. Weaver JU. Classical endocrine diseases causing 
obesity. Front Horm Res. 2008;36:212-228.  
doi: 10.1159/000115367.  
18. Chattrapiban T, Smit HA, Wijga AH, et al. The joint 
effect of maternal smoking during pregnancy and 
maternal pre-pregnancy overweight on infants' 
term birth weight. BMC Pregnancy Childbirth. 
2020 Feb 27;20(1):132.  
doi: 10.1186/s12884-020-2816-3.  
19. Sallis JF, Glanz K. Physical activity and food 
environments: solutions to the obesity epidemic. 
Milbank Q. 2009 Mar;87(1):123-54.  
doi: 10.1111/j.1468-0009.2009.00550.x.  
20. Garcia GD, Pompeo DA, Eid LP, et al. Relationship 
between anxiety, depressive symptoms and 
compulsive overeating disorder in patients with 
cardiovascular diseases. Rev Lat Am 
Enfermagem. 2018 Sep 3;26:e3040.  
doi: 10.1590/1518-8345.2567.3040.  
21. Beccuti G, Pannain S. Sleep and obesity. Curr 
Opin Clin Nutr Metab Care. 2011 Jul;14(4):402-12.  
doi: 10.1097/MCO.0b013e3283479109.  
22. Verhaegen AA, Van Gaal LF. Drugs That Affect 
Body Weight, Body Fat Distribution, and 
Metabolism. [Updated 2019 Feb 11]. In: Feingold 
KR, Anawalt B, Boyce A, et al, editors. Endotext 
[Internet]. South Dartmouth (MA): MDText.com, 
Inc.; 2000-. Available from: 
https://www.ncbi.nlm.nih.gov/books/ 
NBK537590/ 
23. Powell TM, de Lemos JA, Banks K, et al. Body size 
misperception: a novel determinant in the 
obesity epidemic. Arch Intern Med. 2010 Oct 
11;170(18):1695-7.  
Hasanah Dian  CRJIM2(2): November 2021 
 
 CRJIM • Vol 02• Number 2 • November 2021  Page | 214 
doi: 10.1001/archinternmed.2010.314.  
24. Sarwer DB, Polonsky HM. The Psychosocial 
Burden of Obesity. Endocrinol Metab Clin North 
Am. 2016 Sep;45(3):677-88.  
doi: 10.1016/j.ecl.2016.04.016.  
25. Maffetone PB, Laursen PB. The Perfect Storm: 
Coronavirus (Covid-19) Pandemic Meets Overfat 
Pandemic. Frontiers in Public Health. 2020;8 
doi: 10.3389/fpubh.2020.00135]  
26. Ritter A, Kreis NN, Louwen F, et al. Obesity and 
COVID-19: Molecular Mechanisms Linking Both 
Pandemics. Int J Mol Sci. 2020 Aug 
12;21(16):5793.  
doi: 10.3390/ijms21165793  
27. Dias SSG, Soares VC, Ferreira AC, et al. Lipid 
droplets fuel SARS-CoV-2 replication and 
production of inflammatory mediators. PLoS 
Pathog. 2020 Dec 16;16(12):e1009127.  
doi: 10.1371/journal.ppat.1009127.  
28. Pagliaro P, Penna C. ACE/ACE2 Ratio: A Key Also in 
2019 Coronavirus Disease (Covid-19)? Front Med 
(Lausanne). 2020 Jun 18;7:335.  
doi: 10.3389/fmed.2020.00335  
29. Malavazos AE, Corsi Romanelli MM, Bandera F, et 
al. Targeting the Adipose Tissue in COVID-19. 
Obesity (Silver Spring). 2020 Jul;28(7):1178-1179.  
doi: 10.1002/oby.22844. Epub 2020 May 21.  
30. Weaver JU. Classical endocrine diseases causing 
obesity. Front Horm Res. 2008;36:212-228.  
doi: 10.1159/000115367.  
31. Belančić A. Gut microbiome dysbiosis and 
endotoxemia - Additional pathophysiological 
explanation for increased COVID-19 severity in 
obesity. Obes Med. 2020;20:100302. 
doi:10.1016/j.obmed.2020.100302 
32. Belančić A. Gut microbiome dysbiosis and 
endotoxemia - Additional pathophysiological 
explanation for increased COVID-19 severity in 
obesity. Obes Med. 2020 Dec;20:100302.  
doi: 10.1016/j.obmed.2020.100302.  
33. Chowdhury MA, Hossain N, Kashem MA, et al. 
Immune response in COVID-19: A review. J Infect 
Public Health. 2020 Nov;13(11):1619-1629. doi: 
10.1016/j.jiph.2020.07.001.  
34. Sanchis-Gomar F, Lavie CJ, Mehra MR, et al. 
Obesity and Outcomes in COVID-19: When an 
Epidemic and Pandemic Collide. Mayo Clin Proc. 
2020 Jul;95(7):1445-1453.  
doi: 10.1016/j.mayocp.2020.05.006.   
35. Khan AS, Hichami A, Khan NA. Obesity and COVID-
19: Oro-Naso-Sensory Perception. J Clin Med. 
2020 Jul 8;9(7):2158.  
doi: 10.3390/jcm9072158. 
36. Kumar A, Faiq MA, Pareek V, et al. Relevance of 
SARS-CoV-2 related factors ACE2 and TMPRSS2 
expressions in gastrointestinal tissue with 
pathogenesis of digestive symptoms, diabetes-
associated mortality, and disease recurrence in 
COVID-19 patients. Med Hypotheses. 2020 
Nov;144:110271.  
doi: 10.1016/j.mehy.2020.110271 
37. Wang J, Xu Y, Zhang X, et al. Leptin correlates with 
monocytes activation and severe condition in 
COVID‐19 patients. Journal of Leukocyte Biology. 
2021;1-8.  
38. Gorji A, Khaleghi Ghadiri M. Potential roles of 
micronutrient deficiency and immune system 
dysfunction in the coronavirus disease 2019 
(COVID-19) pandemic. Nutrition. 2021 
Feb;82:111047.  
doi: 10.1016/j.nut.2020.111047  
39. Zhao X, Gang X, He G, et al. Obesity Increases the 
Severity and Mortality of Influenza and COVID-19: 
A Systematic Review and Meta-Analysis. Front 
Endocrinol (Lausanne). 2020 Dec 21;11:595109.  
doi: 10.3389/fendo.2020.595109.  
40. Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, 
Zhao HL. Obesity in patients with COVID-19: a 
systematic review and meta-analysis. 
Metabolism. 2020 Dec;113:154378.  
doi: 10.1016/j.metabol.2020.154378. 
41. Honce R, Schultz-Cherry S. Impact of Obesity on 
Influenza A Virus Pathogenesis, Immune 
Response, and Evolution. Front Immunol. 2019 
May 10;10:1071.  
doi: 10.3389/fimmu.2019.01071.  
42. Frayn M, Livshits S, Knäuper B. Emotional eating 
and weight regulation: a qualitative study of 
compensatory behaviors and concerns. J Eat 
Disord. 2018 Sep 14;6:23.  
doi: 10.1186/s40337-018-0210-6  
43. Jura M, Kozak LP. Obesity and related 
consequences to ageing. Age (Dordr). 2016 
Feb;38(1):23.  
doi:10.1007/s11357-016-9884-3.  
44. Apovian CM, Aronne LJ, Bessesen DH, McDonnell 
ME, Murad MH, Pagotto U, Ryan DH, Still CD; 
Endocrine Society. Pharmacological 
management of obesity: an endocrine Society 
clinical practice guideline. J Clin Endocrinol 
Metab. 2015 Feb;100(2):342-62.  
doi: 10.1210/jc.2014-3415.   
45. Stahl JM, Malhotra S. Obesity Surgery Indications 
and Contraindications. [Updated 2020 Jul 31]. In: 
StatPearls [Internet]. Treasure Island (FL): 
StatPearls Publishing;2020 Jan. Available 
from:https://www.ncbi.nlm.nih.gov/books/NBK5
13285/ 
46. Wadden TA, Foster GD. Behavioral treatment of 
obesity. Med Clin North Am. 2000 Mar;84(2):441-
61, vii.  
doi: 10.1016/s0025-7125(05)70230-3. 
47. De Jong A, Wrigge H, Hedenstierna G, et al. How 
to ventilate obese patients in the ICU. Intensive 
Hasanah Dian  CRJIM2(2): November 2021 
 
 CRJIM • Vol 02• Number 2 • November 2021  Page | 215 
Care Med. 2020 Dec;46(12):2423-2435. doi: 
10.1007/s00134-020-06286-x.  
48. WHO recommends life-saving interleukin-6 
receptor blockers for COVID-19 and urges 
procedures to join efforts to rapidly increase 






49. Pasquali R, Oriolo C. Obesity and Androgens in 
Women. Front Horm Res. 2019;53:120-134. doi: 
10.1159/000494908.  
50. Baratchian M, McManus JM, Berk MP, et al. 
Androgen regulation of pulmonary AR, TMPRSS2 
and ACE2 with implications for sex-discordant 
COVID-19 outcomes. Sci Rep. 2021 May 
27;11(1):11130.doi:10.1038/s41598-021-90491-1.  
51. Garg S, Kim L, Whitaker M, et al. Hospitalization 
Rates and Characteristics of Patients Hospitalized 
with Laboratory-Confirmed Coronavirus Disease 
2019 - COVID-NET, 14 States, March 1-30, 2020. 
MMWR Morb Mortal Wkly Rep. 2020 Apr 
17;69(15):458-464. doi: 
10.15585/mmwr.mm6915e3. P 
52. Cohen PG. Obesity in men: the hypogonadal-
estrogen receptor relationship and its effect on 
glucose homeostasis. Med Hypotheses. 
2008;70(2):358-60.doi:10.1016/j.mehy.2007.05.020 
53. Liu H, Liu K, Bodenner DL. Estrogen receptor 
inhibits interleukin-6 gene expression by 
disruption of nuclear factor kappaB 
transactivation. Cytokine. 2005 Aug 21;31(4):251-
7. doi: 10.1016/j.cyto.2004.12.008.  
54. Schneider G, Kirschner MA, Berkowitz R, et al. 
Increased estrogen production in obese men. J 
Clin Endocrinol Metab. 1979 Apr;48(4):633-8. doi: 
10.1210/jcem-48-4-633.  
55. Montopoli M, Zumerle S, Vettor R, et al. Androgen-
deprivation therapies for prostate cancer and risk 
of infection by SARS-CoV-2: a population-based 
study (N = 4532). Ann Oncol. 2020 Aug;31(8):1040-
1045. doi: 10.1016/j.annonc.2020.04.479.  
56. Jia D, Taguchi M, Otsuki M. Synthetic protease 
inhibitor camostat prevents and reverses 
dyslipidemia, insulin secretory defects, and 
histological abnormalities of the pancreas in 
genetically obese and diabetic rats. Metabolism. 
2005 May;54(5):619-27. doi: 
10.1016/j.metabol.2004.12.005.  
57. Daewoong Pharmaceutical [Internet]. Daewoong 
Pharmaceutical AnnoucesCamostat Achieving 
50% Faster Recovery Time for Mild COVID-19 
Patients Over Age of 50 in Topline Results from 
Phase 2B Clinical Trial; 2021 [update July 29, 







58. Hofmann-Winkler H, Moerer O, Alt-Epping S, et al. 
Camostat Mesylate May Reduce Severity of 
Coronavirus Disease 2019 Sepsis: A First 
Observation. Crit Care Explor. 2020 Nov 
16;2(11):e0284. doi: 
10.1097/CCE.0000000000000284.  
59. Liu SY, Aliyari R, Chikere K, et al. Interferon-
inducible cholesterol-25-hydroxylase broadly 
inhibits viral entry by production of 25-
hydroxycholesterol. Immunity. 2013 Jan 
24;38(1):92-105. doi: 
10.1016/j.immuni.2012.11.005.  
60. Rodrigues-Diez RR, Tejera- Muñoz A, Marquez-
Exposito L, et al. Statins: could an old friend help 
the fight against COVID-19? Br J Pharmacol. 
(2020). doi: 10.1111/bph.15166.  
61. Paris GC, Azevedo AA, Ferreira AL, et al. 
Therapeutic potential of mesenchymal stem cells 
in multiple organs affected by COVID-19. Life Sci. 
2021 Aug 1;278:119510. doi: 
10.1016/j.lfs.2021.119510.  
 
